Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuta Myojin

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Gastroenterology|February 27, 2026
Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive HepatopathySeiya Kato, Hayato Hikita, Osamu Tsukamoto, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver TransplantationLorenz Kocheise, Gabriel Bacil, Pavan Bhimalli, et al.
Cancer Medicine|January 11, 2024
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinomaCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 11, 2026
Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis BEmi Sometani, Kazuhiro Murai, Hayato Hikita, et al.
Gut|September 28, 2023
Immunosuppressive CD29<sup>+</sup> Treg accumulation in the liver in mice on checkpoint inhibitor therapyBenjamin L Green, Yuta Myojin, Chi Ma, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2024
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosisShusuke Kumazaki, Hayato Hikita, Yuki Tahata, et al.
Hepatology Communications|June 3, 2024
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLDSadatsugu Sakane, Hayato Hikita, Kumiko Shirai, et al.
Cancers|July 27, 2022
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination ImmunotherapyTakayuki Matsumae, Takahiro Kodama, Yuta Myojin, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2021
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Gastroenterology|February 27, 2026
Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive HepatopathySeiya Kato, Hayato Hikita, Osamu Tsukamoto, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver TransplantationLorenz Kocheise, Gabriel Bacil, Pavan Bhimalli, et al.
Cancer Medicine|January 11, 2024
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinomaCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 11, 2026
Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis BEmi Sometani, Kazuhiro Murai, Hayato Hikita, et al.
Gut|September 28, 2023
Immunosuppressive CD29<sup>+</sup> Treg accumulation in the liver in mice on checkpoint inhibitor therapyBenjamin L Green, Yuta Myojin, Chi Ma, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2024
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosisShusuke Kumazaki, Hayato Hikita, Yuki Tahata, et al.
Hepatology Communications|June 3, 2024
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLDSadatsugu Sakane, Hayato Hikita, Kumiko Shirai, et al.
Cancers|July 27, 2022
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination ImmunotherapyTakayuki Matsumae, Takahiro Kodama, Yuta Myojin, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2021
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Pageof 4